论文部分内容阅读
目的探讨去甲氧柔红霉素联合FLAG方案(IDA-FLAG方案)治疗复发难治的急性白血病的疗效评价。方法选择2010年1月至2012年1月期间洛阳市中心医院诊治的60例复发难治性白血病患者,随机将其分为对照组和观察组,每组30例,分别给予FLAG方案治疗和IDA-FLAG方案治疗,对两组的临床疗效、不良反应进行观察和比较。结果与对照组相比(63.3%),观察组的缓解率明显升高(93.3%),差异有统计学意义(P<0.05);与对照组相比(40.0%),观察组不良反应发生率没有明显改变(53.3%),差异无统计学意义(P>0.05)。结论对于复发难治的急性白血病患者,IDA-FLAG方案疗效显著,有利于提高患者的预后质量。
Objective To investigate the efficacy of demethoxyribromide combined with FLAG regimen (IDA-FLAG regimen) in the treatment of relapsed and refractory acute leukemia. Methods Sixty patients with relapsed and refractory leukemia diagnosed and treated in Central Hospital of Luoyang from January 2010 to January 2012 were randomly divided into control group and observation group with 30 cases in each group and received FLAG regimen and IDA -FLAG program treatment, the clinical efficacy of the two groups, adverse reactions were observed and compared. Results Compared with the control group (63.3%), the remission rate of the observation group was significantly higher (93.3%), the difference was statistically significant (P <0.05). Compared with the control group (40.0%), the adverse reactions of the observation group The rate did not change significantly (53.3%), the difference was not statistically significant (P> 0.05). Conclusion The IDA-FLAG regimen is effective in improving the prognosis of patients with relapsed and refractory acute leukemia.